What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Antibiotics/Anti-infectives

EXLLA DROP

Cefpodoxime Proxetil 25mg Oral Suspension

Pack: 10ML
Format: With Carton

MRP₹79.69

A specialized, precision-dosed third-generation cephalosporin antibacterial drop designed for infants and neonates. EXLLA DROPS provides targeted, broad-spectrum coverage to rapidly clear delicate respiratory, ear, and urinary tract infections in the youngest patients.

About The Product

Key Benefits

Precision Dosing for Infants

The concentrated drop formulation (25mg Cefpodoxime) is specifically engineered to provide therapeutic efficacy in very small volumes. This ensures that infants receive the full medicinal dose without the struggle of swallowing large amounts of liquid, reducing the risk of spitting up or dosage inaccuracies.

Targeteddd Pediatric Bactericidal Action

Cefpodoxime Proxetil 25mg is a potent third-generation cephalosporin that works by inhibiting bacterial cell wall synthesis. This rapid bactericidal action is critical for treating infant conditions like Acute Otitis Media (middle ear infection) and early-stage respiratory tract infections before they can progress to more severe complications.

Superior Stability and Tissue Penetration

Cefpodoxime Proxetil is known for its exceptional ability to penetrate deep into lung and sinus tissues. This ensures that the antibiotic reaches the site of infection in high concentrations, providing a faster clinical response and reducing the duration of fever and discomfort in infants.

High Bioavailability and Safety

EXLLA DROPS are formulated for rapid absorption in the infant gastrointestinal tract. The concentration is clinically optimized to provide maximum antibacterial coverage while remaining gentle on the developing digestive system of a baby, ensuring a high safety margin.

Broad-Spectrum Infant Care

This formulation is highly effective against a wide array of Gram-positive and Gram-negative bacteria, including resistant strains that might defeat older penicillins. It serves as a frontline defense for neonatal and infant infections where reliability and safety are paramount.

Ease of Administration

The inclusion of a calibrated dropper allows parents and caregivers to measure the exact milligram dose required based on the infant's body weight. This level of precision is vital in neonatal care to ensure the infection is cleared while maintaining an excellent safety profile.

Indication Acute Otitis Media (Middle Ear Infection) in Infants, Neonatal/Infant Skin and Soft Tissue Infections, Acute Sinusitis and Tonsillitis, Early-Stage Bronchitis and Pneumonia, Urinary Tract Infections in Infants.

Indications

Acute Otitis Media (Middle Ear Infection) in Infants
Neonatal/Infant Skin and Soft Tissue Infections
Acute Sinusitis and Tonsillitis
Early-Stage Bronchitis and Pneumonia
Urinary Tract Infections in Infants.

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

EXLLA DROP